{"id":88803,"date":"2026-10-26T12:35:00","date_gmt":"2026-10-26T12:35:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=88803"},"modified":"2026-10-27T02:00:20","modified_gmt":"2026-10-27T02:00:20","slug":"pluri-and-zeo-scientifix-partner-to-expand-u-s-manufacturing-and-commercial-platform-for-regenerative-medicine","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/pluri-and-zeo-scientifix-partner-to-expand-u-s-manufacturing-and-commercial-platform-for-regenerative-medicine\/","title":{"rendered":"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine"},"content":{"rendered":"<p><em>Partnership combines Pluri\u2019s proprietary cell technology and clinical-development experience with ZEO\u2019s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure<\/em><\/p>\n<ul>\n<li style=\"text-align:justify;\"><strong>Established U.S. commercial platform:<\/strong> ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources.<\/li>\n<li style=\"text-align:justify;\"><strong>Complementary technology and development capabilities:<\/strong> Pluri brings extensive experience in cell-based product development, clinical experience extending through Phase III trials and scalable manufacturing methods and expertise developed through its proprietary 3D cell-expansion platform.<\/li>\n<li style=\"text-align:justify;\"><strong>Broader product and clinical-development opportunities:<\/strong> The companies intend to expand commercial offerings, including regenerative aesthetics, and combine scientific resources to strengthen and advance selected clinical programs.<\/li>\n<li style=\"text-align:justify;\"><strong>Aligned ownership:<\/strong> The transaction and contemplated additional share exchange will result in Pluri owning 50% of ZEO at Closing following the completion of the applicable transaction steps.<strong>\u00a0<\/strong><\/li>\n<\/ul>\n<p align=\"justify\">HAIFA, Israel and FORT LAUDERDALE, Fla., Oct.  26, 2026  (GLOBE NEWSWIRE) &#8212; Pluri Inc. (Nasdaq and TASE: PLUR) (\u201cPluri\u201d) and ZEO ScientifiX, Inc. (OTCQB: ZEOX) (\u201cZEO\u201d) today announced a definitive strategic agreement (\u201cPartnership Agreement\u201d) to expand the parties U.S. manufacturing and commercialization platform serving the regenerative medicine, aesthetics, wellness, and longevity markets.<\/p>\n<p align=\"justify\">ZEO brings an established U.S. biologics business combining scientific and manufacturing capabilities with the infrastructure needed to reach and support physicians. Its existing biologics portfolio, substantial physician network, established sales channel, dedicated marketing department, and educational programming provide a foundation for introducing additional products and expanding commercial operations.<\/p>\n<p align=\"justify\">Pluri contributes more than two decades of experience in cell-based research, product development, clinical trials, process scale-up, quality systems, and manufacturing. Its proprietary three-dimensional cell-expansion technology and intellectual property support the development and manufacture of cell-based products and its Cellav Health and Aesthetics Ltd.\u2019s (\u201cCellav\u201d) regenerative aesthetics portfolio.<\/p>\n<p align=\"justify\">Together, the companies intend to connect these complementary capabilities to broaden product offerings, expand commercial reach, and strengthen selected regenerative-development programs, subject to applicable regulatory requirements.<\/p>\n<p><strong>Expanding Opportunities in Regenerative Aesthetics<\/strong><\/p>\n<p align=\"justify\">The Partnership Agreement also provides for exclusive U.S. rights to Pluri\u2019s Cellav aesthetic product line, including future offerings. Cellav, Pluri\u2019s wholly owned aesthetics subsidiary, develops cell-derived ingredients and aesthetic products that the companies intend to introduce through ZEO\u2019s commercial platform.<\/p>\n<p><strong>Advanced Product Development<\/strong><\/p>\n<p align=\"justify\">Pluri brings more than two decades of clinical-development expertise, including multinational Phase III trials in muscle recovery following hip-fracture surgery and critical limb ischemia (CLI), supported by extensive scientific and clinical data and an intellectual property portfolio of over 200 patents. By combining Pluri\u2019s accumulated knowledge and development experience with ZEO\u2019s research, manufacturing, and commercial capabilities, the companies aim to develop and bring to market advanced therapeutic products, supported by scientific evidence and informed by extensive clinical data.<\/p>\n<p align=\"justify\"><strong>Leadership Perspectives<\/strong><\/p>\n<p align=\"justify\"><strong>Ian Bothwell, Chief Executive Officer of ZEO ScientifiX<\/strong> commented: \u201cPluri brings capabilities that are exceptionally valuable to our business: proprietary cell technology, two decades of scientific and clinical experience, and proven expertise in scalable cell manufacturing. We believe combining these strengths with ZEO\u2019s scientific expertise and commercial infrastructure will allow us to expand our product portfolio, accelerate innovation, and pursue opportunities that neither company could address as effectively on its own. We are excited to partner with Pluri and build a stronger platform for the future of regenerative medicine.\u201d<\/p>\n<p align=\"justify\"><strong>Yaky Yanay, President and Chief Executive Officer of Pluri<\/strong> commented: \u201cZEO has built something highly valuable: an established U.S. commercial platform with direct access to physicians, an existing advanced product portfolio, and dedicated sales, marketing, and educational capabilities. For Pluri, this creates an important opportunity to connect more than two decades of cell technology, clinical development, and advanced manufacturing expertise with an existing route to market. We believe this partnership can accelerate commercialization, expand our reach in the U.S., and support our ambition to build a growing regenerative medicine business.\u201d<\/p>\n<p><strong>Transaction Overview<\/strong><\/p>\n<p align=\"justify\">Under the Partnership Agreement, Pluri will grant ZEO defined rights to its manufacturing technology and related know-how for associated with its regenerative medicine associated assets, while retaining ownership of its underlying technology and intellectual property. In consideration, ZEO will initially issue shares of its common stock representing 50% of its issued and outstanding common stock immediately following Closing. The Partnership Agreement also provides for warrants, corporate governance and protective rights, among other matters, as well as customary representations and warranties, covenants and indemnifications of the parties.<\/p>\n<p align=\"justify\">Following closing, ZEO\u2019s financial results are expected to be consolidated into Pluri\u2019s financial statements, subject to applicable accounting requirements.<\/p>\n<p align=\"justify\">Closing of the proposed transaction, which is expected to occur in the fourth quarter of 2026 is subject to satisfaction of a number of conditions, including the negotiation of various ancillary agreements, securing certain approvals and the delivery of valuations, as well as other customary closing conditions. The transaction is not subject to stockholder approval by either Pluri or ZEO.<\/p>\n<p><strong>About Pluri<\/strong><\/p>\n<p align=\"justify\">Pluri&#x2122; is a biotechnology company advancing cell-based solutions for health and longevity. Powered by its proprietary 3D cell expansion platform, Pluri develops and manufactures innovative cell-based products designed to address significant unmet medical needs and support healthier, longer lives. With decades of expertise in cell science, clinical development and scalable manufacturing, Pluri is building a portfolio of regenerative and longevity-focused solutions while leveraging its technology and manufacturing capabilities through strategic partnerships. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XjXtYZ4swxmUA6c0-OVNZjyvKAOYaHsJYA07tAw2tgugsE3KD3F7ecwhcRoLtMC0096ipIs6R07j0JgE6Rx8FJCw0sk-6Mu0gJmRaYZkapc=\" rel=\"nofollow\" target=\"_blank\" title=\"www.pluri-biotech.com\">www.pluri-biotech.com<\/a> or follow Pluri on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UwKX-B94ZxL23eI73oSG75GdpzdVKdZOKZP-Ga4IJZMXKtzp0dVroZq9AUxzEvsUf4yhaO9M-54UgpcqEexrmWGt65mqtcYpa_ckrZw9nC01UiqgBkW-gzLutBvIhK0C\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn <\/a>and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nlfb6Px2Mn1U7SqppuvzGUjBgtF6s13w4qPZBy-GYaBaYxBC5Q4fhYFi_uxo7VglWHeaxN5qlhwVgiFnfJb3FQ==\" rel=\"nofollow\" target=\"_blank\" title=\"X\">X<\/a>.<\/p>\n<p><strong>About ZEO ScientifiX<\/strong><\/p>\n<p align=\"justify\">ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a U.S. biopharmaceutical company integrating regenerative biologics research, development, and manufacturing with established commercial operations. Based at Nova Southeastern University\u2019s Center for Collaborative Research in Davie, Florida, ZEO combines scientific and manufacturing expertise with a substantial physician network, dedicated sales and marketing resources, and physician education infrastructure. Through internal development and strategic partnerships, ZEO seeks to expand its product portfolio and advance regenerative medicine. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ytS9VmI3-94l6vtBd1Nhb5RaMkXS78gJKHPLWoMDabqR5zZBTTYtfQCgxDXXLT9HJzoX3pYZ8UBqat5tl3H5rSwM2XKJxrkvvF1KU3gecQs=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.zeoscientifix.com<\/u><\/a> or follow ZEO on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UwKX-B94ZxL23eI73oSG7zUW4Ftvi7GmSeSHYjGlPMo6PMu2wfpFJGsSu8Hhb3dCFLX3sr6aykvN4jH07OQmOoIAFgUFtRbQP-gFR9Iar90RDFYgyyF5zV4xP7hBqC9x\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hEyBVe1ZlA6ja_fx67Snf1oNIvRdQ0dOEWvN9_A_0C3w216gajfwmhPV8oy86hzqcnMSvRhe2MAXnBmzKnK7bobQcNKgZtUUw2T-3Haba2_fsY4DRr571OuPDzvDD_WCs2qaqu6iTOncHTSq8WqgyA==\" rel=\"nofollow\" target=\"_blank\" title=\"Facebook\">Facebook <\/a>and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fN1VR9iVwdyzfvLdkS3oQKIJy5olkDP8371S8fYepgK66Ihy6tZxZRXGfZaUqSHpgagAJMbpfZOtsCblFXzKnxkjUPz0X4oguRp9wK3HpDU=\" rel=\"nofollow\" target=\"_blank\" title=\"Instagram\">Instagram<\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable U.S. securities laws, including statements regarding transaction completion and timing; licensing, ownership, and accounting consolidation; integration; product development and commercialization; clinical programs, and anticipated strategic and financial benefits.<\/p>\n<p align=\"justify\">Actual results could differ materially due to risks including failure to complete the transaction; integration challenges; insufficient funding; unsuccessful development, clinical trials, or commercialization; manufacturing and supply issues; competition; and changes in applicable federal and state regulatory requirements. Prior clinical experience does not assure future success.<\/p>\n<p align=\"justify\">Additional risks are described in the companies\u2019 respective SEC filings. Neither company undertakes to update forward-looking statements except as required by law.<\/p>\n<p><strong>Contacts<\/strong><\/p>\n<p><strong>Pluri Investor Relations<\/strong><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OS_VL7X15zoHztSjgN36Anyai8Xr2j1HQH0X0lAs8m8uhznfbuodyrSCg06U_uuR_fLdeeQSzuHWsZZrbVIQt0zjRVEHCLoa0yQHinyY_1G0yzR6D2ck-3axz0AxwJT3lX7xtT6rlX94NBDCbW06wg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>investor.relations@pluri-biotech.com<\/u><\/a><\/p>\n<p><strong>ZEO ScientifiX<\/strong><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OS_VL7X15zoHztSjgN36AnQsrVzPjHPIRp_7Hc1idypv0fYpqiEJeUZ69X0iOZXZVVMfWF7WYCtpJlR69bxbm3C4tN5uJuoSrpPGExtooa_e7sAPnfiRwc54sOqrNOIifZi21tkeW-QPEMquUMbwjg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>investor.relations@zeoscientifix.com<\/u><\/a><\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gAbIsU9rhBW-Uip8NQPx_qwSg6eLjRXTuNqxSM-JFC9zFrgFU_jBTZ1NV6HLd03PfM59XSTTxpaPaAhZ_5r7PDAQPTG3IrwpQ3kSpPPxGaB6YPtWQxnMN1DhcEP2ZimMiVHovZVmLfaOxG9fQ9CmQ_ZwMY3qVgCcUSPwXdzeUZXc1jKivWyA6-HcVk2q2IzBLjdPaqe33XkjgvKcNDJ4LvoeoNhgvP7fvRHTM8fi1UrhRg95rG9A_k0eCcFtEpZZsGsftfzQHZhJtHg2-5FUiw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/200b1de8-e87f-403d-83cc-f13752007908<\/a><\/p>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/ZDEzMjRlYjYtNmVmZC00MGNjLTg2MDktYjU4MzRiMjA0ZDNjLTEwMjkxNjktMjAyNi0xMC0yNi1lbg==\/tiny\/Pluri-Inc-.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Partnership combines Pluri\u2019s proprietary cell technology and clinical-development experience with ZEO\u2019s biologics manufacturing expertise, established physician network, and sales, marketing, and educational infrastructure Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and educational resources. Complementary technology and development capabilities: Pluri brings extensive experience [&#8230;]\n","protected":false},"author":1,"featured_media":88804,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-88803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine\" \/>\n<meta property=\"og:description\" content=\"Partnership combines Pluri\u2019s proprietary cell technology and clinical-development experience with ZEO\u2019s biologics manufacturing expertise, establi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-26T12:35:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T02:00:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/saigonbiz-media-slogan-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"563\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine\",\"datePublished\":\"2026-10-26T12:35:00+00:00\",\"dateModified\":\"2026-10-27T02:00:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\"},\"wordCount\":1137,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/?p=88803#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\",\"name\":\"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-10-26T12:35:00+00:00\",\"dateModified\":\"2026-10-27T02:00:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/?p=88803\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/?p=88803#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/?p=88803","og_locale":"en_US","og_type":"article","og_title":"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine","og_description":"Partnership combines Pluri\u2019s proprietary cell technology and clinical-development experience with ZEO\u2019s biologics manufacturing expertise, establi","og_url":"https:\/\/english.saigonbiz.com\/vn\/?p=88803","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-10-26T12:35:00+00:00","article_modified_time":"2026-10-27T02:00:20+00:00","og_image":[{"width":1000,"height":563,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/09\/saigonbiz-media-slogan-3.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/?p=88803#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/?p=88803"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine","datePublished":"2026-10-26T12:35:00+00:00","dateModified":"2026-10-27T02:00:20+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/?p=88803"},"wordCount":1137,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/?p=88803#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/?p=88803","url":"https:\/\/english.saigonbiz.com\/vn\/?p=88803","name":"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-10-26T12:35:00+00:00","dateModified":"2026-10-27T02:00:20+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/?p=88803#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/?p=88803"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/?p=88803#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=88803"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88803\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/88804"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=88803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=88803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=88803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}